Drug price history · CMS NADAC read 11 November 2026
Generic
$73.78 per unit at the 2018 year-end survey (4 NDCs) and $45.11 at the 2026 survey (9 NDCs): −39%.
| Year-end survey | Median per unit | Lowest to highest | NDCs priced |
|---|---|---|---|
| 2018 (2018-12-26) | $73.78 | 4 | |
| 2019 (2019-12-25) | $74.70 | 4 | |
| 2020 (2020-12-30) | $79.92 | 4 | |
| 2021 (2021-12-29) | $66.75 | 6 | |
| 2022 (2022-12-28) | $52.79 | 7 | |
| 2023 (2023-12-27) | $74.05 | 7 | |
| 2024 (2024-12-25) | $38.18 | 7 | |
| 2025 (2025-12-31) | $47.49 | 7 | |
| 2026 (2026-11-11) | $45.11 | 9 |
Generic
$153 per unit at the 2020 year-end survey (2 NDCs) and $85.19 at the 2026 survey (4 NDCs): −44%, a thin comparison.
| Year-end survey | Median per unit | Lowest to highest | NDCs priced |
|---|---|---|---|
| 2020 (2020-12-30) | $153 | 2 | |
| 2021 (2021-12-29) | $145 | 3 | |
| 2023 (2023-12-27) | $151 | 3 | |
| 2024 (2024-12-25) | $73.28 | 3 | |
| 2025 (2025-12-31) | $111 | 3 | |
| 2026 (2026-11-11) | $85.19 | 4 |
Generic
$130 per unit at the 2021 year-end survey (7 NDCs) and $78.69 at the 2026 survey (13 NDCs): −39%.
| Year-end survey | Median per unit | Lowest to highest | NDCs priced |
|---|---|---|---|
| 2021 (2021-12-29) | $130 | 7 | |
| 2023 (2023-12-27) | $76.08 | 9 | |
| 2024 (2024-12-25) | $102 | 9 | |
| 2025 (2025-12-31) | $79.78 | 10 | |
| 2026 (2026-11-11) | $78.69 | 13 |
Generic
$182 per unit at the 2024 year-end survey (6 NDCs) and $112 at the 2026 survey (8 NDCs): −38%.
| Year-end survey | Median per unit | Lowest to highest | NDCs priced |
|---|---|---|---|
| 2024 (2024-12-25) | $182 | 6 | |
| 2025 (2025-12-31) | $164 | 6 | |
| 2026 (2026-11-11) | $112 | 8 |
CMS National Average Drug Acquisition Cost, year-end surveys 2013 to 2026. A pharmacy acquisition cost, not a retail price. About NADAC.
The FDA Orange Book lists 3 generic makers as marketed in its largest dosage form for Aprepitant, and the first generic approval is dated 24 September 2012. The acquisition costs above are what pharmacies pay across the NDCs priced; the Orange Book count is a separate record and this page does not say that more makers lowered a price. See each maker and the patents still listed on OmniRx.
Open it in the check to search another drug, or see the CMS pharmacy pricing page for what NADAC measures. For who makes the generic and which patents are listed, see the generic competition check for Aprepitant on OmniRx. To check whether a drug is in shortage, see the FDA drug shortages page.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the CMS pharmacy pricing page, year-end surveys 2013 to 2026 (latest 11 November 2026).